Skip to main content

Advertisement

SpringerLink
Log in

Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Granulocyte or granulocyte-macrophage colony stimulating factor (CSF), usually used in conjunction with chemotherapy, may interfere with the 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) reading. The purpose of this study is to evaluate the effects of CSF, conventional-or high-dose chemotherapy on bone marrow FDG uptake.

Methods

Two hundred and forty-one FDG PET scans obtained in 163 patients with lymphoma and no pathologically and radiologically proven bone marrow involvement were analyzed. The standardized uptake value (SUV) of each patient’s spine was measured.

Results

Among patients with no recent history of CSF use, the average SUV in 36 patients with no history of chemotherapy was 1.60±0.34, that in 49 patients with a history of conventional-dose chemotherapy was 1.37±0.32, and that in 12 patients with a history of high-dose chemotherapy was 1.26±0.25 (P=0.008 and 0.002, respectively by Mann-Whitney U test). In 80 patients treated with conventional-dose chemotherapy and CSF, the average SUV after discontinuation of CSF was as follows: 0–7 days, 2.37±1.19; 8–14 days: 2.04±0.67; 15–21 days: 1.87±0.52; 22–30 days: 1.59±0.18; 31–90 days: 1.54±0.36. In 45 patients treated with high-dose chemotherapy and CSF, no significant increase in bone marrow uptake was seen in most of them.

Conclusion

Bone marrow FDG uptake may be increased by CSF treatment and may be decreased by chemotherapy. In patients treated with conventional-dose chemotherapy and CSF, increased marrow uptake will return to the pretreatment value approximately 1 month after discontinuation of CSF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603–9

    PubMed  Google Scholar 

  2. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–13

    PubMed  Google Scholar 

  3. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11

    PubMed  Google Scholar 

  4. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475–81

    PubMed  Google Scholar 

  5. Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, Timothy AR. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–6

    PubMed  Google Scholar 

  6. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224–39

    PubMed  Google Scholar 

  7. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–80

    PubMed  Google Scholar 

  8. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1995;86:457–62

    PubMed  Google Scholar 

  9. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773–8

    PubMed  Google Scholar 

  10. Yao WJ, Hoh CK, Hawkins RA, Glapsy JA, Weil JA, Lee SJ. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995;36:794–9

    PubMed  Google Scholar 

  11. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996;23:845–9

    Article  PubMed  Google Scholar 

  12. Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1997;23:93–8

    Article  Google Scholar 

  13. Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 2002;27:140–1

    Article  PubMed  Google Scholar 

  14. Corder MP, Jochimsen PR. Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast. Cancer 1982;49:2455–8

    PubMed  Google Scholar 

  15. Lohrmann HP, Schreml W, Lang M, Betzler M, Fliedner TM, Heimpel H. Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer. Br J Haematol 1978;40:369–81

    PubMed  Google Scholar 

  16. Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993;32:450–4

    Article  PubMed  Google Scholar 

  17. Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30:S28–36

    PubMed  Google Scholar 

  18. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997;15:2981–95

    PubMed  Google Scholar 

  19. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–50

    PubMed  Google Scholar 

  20. Higashi T, Fisher SJ, Brown RS, Nakada K, Walter GL, Wahl RL. Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. J Nucl Med 2000;41:2026–35

    PubMed  Google Scholar 

  21. Meyer MA, Nathan CA. Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation. Clin Nucl Med 2000;25:279–80

    Article  PubMed  Google Scholar 

  22. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 2000;20:713–23

    PubMed  Google Scholar 

  23. Matthies A, Schuster SJ, Alavi A. Staging and monitoring response to treatment in primary non-Hodgkin’s lymphoma of bone marrow using 18F-fluorodeoxyglucose positron emission tomography. Clin Lymphoma 2001;1:303–6

    PubMed  Google Scholar 

  24. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25:191–207

    PubMed  Google Scholar 

  25. Chiang SB, Rebenstock A, Guan L, Alavi A, Zhuang H. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med 2003;28:674–6

    Article  PubMed  Google Scholar 

  26. Takalkar A, Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med 2004;29:637–9

    Article  PubMed  Google Scholar 

  27. Plantade A, Montravers F, Selle F, Izrael V, Talbot JN. Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. Clin Nucl Med 2003;28:771–2

    Article  PubMed  Google Scholar 

  28. Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin’s lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62–4

    PubMed  Google Scholar 

  29. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001;28:155–64

    Article  PubMed  Google Scholar 

  30. Caballero MD, Vazquez L, Barragan JM, Cruz JJ, Gomez A, Nieto MJ, et al. Randomized study of filgrastim versus molgramostim after peripheral stem cell transplant in breast cancer. Haematologica 1998;83:514–8

    PubMed  Google Scholar 

  31. Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998;16:366–73

    Google Scholar 

Download references

Acknowledgements

The authors thank Beth Wagner for the literature search, and Mary J. Hansen and Carol L. Kimball M.P.H., R.Ph. for search of prescription history.

Author information

Author notes

  1. Toshiki Kazama

    Present address: Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

Authors and Affiliations

  1. Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA

    Toshiki Kazama, Nancy Swanston, Donald A. Podoloff & Homer A. Macapinlac

Authors
  1. Toshiki Kazama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy Swanston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald A. Podoloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Homer A. Macapinlac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiki Kazama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kazama, T., Swanston, N., Podoloff, D.A. et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 32, 1406–1411 (2005). https://doi.org/10.1007/s00259-005-1890-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1890-0

Keywords

Search

Navigation